Aigen Investment Management LP Buys Shares of 71,714 R1 RCM Inc. (NASDAQ:RCM)

Aigen Investment Management LP purchased a new stake in shares of R1 RCM Inc. (NASDAQ:RCM) during the 4th quarter, Holdings Channel.com reports. The fund purchased 71,714 shares of the healthcare provider’s stock, valued at approximately $758,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of RCM. Van ECK Associates Corp lifted its position in R1 RCM by 20.5% during the fourth quarter. Van ECK Associates Corp now owns 6,141 shares of the healthcare provider’s stock valued at $65,000 after purchasing an additional 1,044 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of R1 RCM by 4.2% in the third quarter. Victory Capital Management Inc. now owns 31,275 shares of the healthcare provider’s stock worth $471,000 after purchasing an additional 1,250 shares during the last quarter. Pathstone Family Office LLC increased its holdings in shares of R1 RCM by 6.1% in the third quarter. Pathstone Family Office LLC now owns 32,638 shares of the healthcare provider’s stock worth $492,000 after purchasing an additional 1,867 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of R1 RCM in the third quarter worth about $36,000. Finally, Mariner LLC increased its holdings in shares of R1 RCM by 10.6% in the third quarter. Mariner LLC now owns 29,508 shares of the healthcare provider’s stock worth $445,000 after purchasing an additional 2,836 shares during the last quarter. 61.10% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on RCM. Canaccord Genuity Group reduced their target price on R1 RCM from $16.00 to $15.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Citigroup raised R1 RCM from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Wednesday, March 20th. KeyCorp reissued a “sector weight” rating on shares of R1 RCM in a research note on Wednesday, April 10th. SVB Leerink assumed coverage on R1 RCM in a research note on Monday, February 26th. They set an “outperform” rating and a $14.00 price objective on the stock. Finally, Leerink Partnrs reissued an “outperform” rating on shares of R1 RCM in a research note on Monday, February 26th. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $16.31.

Insider Activity at R1 RCM

In other R1 RCM news, President John M. Sparby sold 10,046 shares of the stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $14.33, for a total transaction of $143,959.18. Following the sale, the president now directly owns 265,986 shares of the company’s stock, valued at approximately $3,811,579.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 36.80% of the stock is owned by insiders.

R1 RCM Trading Down 0.1 %

Shares of NASDAQ RCM traded down $0.01 during trading hours on Wednesday, reaching $12.27. The stock had a trading volume of 348,849 shares, compared to its average volume of 3,366,374. The company has a current ratio of 1.79, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78. The firm has a market cap of $5.17 billion, a price-to-earnings ratio of -153.50 and a beta of 0.78. The business’s fifty day moving average price is $12.56 and its two-hundred day moving average price is $11.51. R1 RCM Inc. has a 52-week low of $8.87 and a 52-week high of $18.70.

R1 RCM (NASDAQ:RCM) last posted its earnings results on Wednesday, May 8th. The healthcare provider reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). The company had revenue of $603.90 million for the quarter, compared to analysts’ expectations of $612.88 million. R1 RCM had a negative return on equity of 1.16% and a negative net margin of 1.39%. The business’s quarterly revenue was up 10.7% compared to the same quarter last year. Analysts expect that R1 RCM Inc. will post -0.09 EPS for the current fiscal year.

About R1 RCM

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.